James Hickman,
Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering,
University of Central Florida; Chief Scientist, Hesperos
James J. Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Biomedical Engineering, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past thirty years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is also the founder and current Chief Scientist of a biotechnology company, Hesperos, that is focusing on cell-based systems for drug discovery and toxicity. He has 166 publications and 20 book chapters, in addition to 34 issued patents out of 50 total patent applications. He was elected to the Board of Directors of the American Institute for Medical and Biological Engineering (AIMBE) for 2 consecutive terms, the premier society for Biomedical Engineering of which he is a Fellow. He is also a Fellow of the American Vacuum Society (AVS) and National Academy of Inventors (NAI) as well as BioFlorida’s Researcher of the Year (2022). Dr. Hickman along with Dr. Michael Shuler, won the Lush Prize, in the Science Category, which Supports Animal Free Testing in 2015.
Concurrent Toxicity and Efficacy Evaluations in Multi-Organ Functional Human-on-a-Chip Systems
Wednesday, 6 June 2018 at 09:30
Add to Calendar ▼2018-06-06 09:30:002018-06-06 10:30:00Europe/LondonConcurrent Toxicity and Efficacy Evaluations in Multi-Organ Functional Human-on-a-Chip SystemsOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The current drug development process is inefficient, taking years from target compound identification to marketable drug, and costs up to 2 billion dollars during the process. The considerable attrition-rate of drug candidates at all stages of development to a significant extent arises from the poor predictive nature of preclinical models for efficacy and toxicity, especially the inability to translate efficacy between preclinical and clinical situations. Systems capable of directly measuring organ function, biomarker release, and most importantly the synergistic interactions between organs, especially the generation of liver metabolites would be ideal. Body-on-a-chip systems utilize function based cell models that accurately capture and predict multi organ complexity in response to administered compound within correctly scaled and physiologically relevant platforms. This data can then theoretically be used to produce relevant modeling information related to drug responses in clinical settings, and thereby provide accurate predictions of a compound’s patient specific toxicology and efficacy. We have demonstrated functional human models to evaluate multi-organ toxicity in 2-, 3- and 4-organ systems under continuous flow conditions in a serum-free defined medium utilizing a pumpless platform for 28 days with cardiac, muscle, cancer, neuronal and liver modules. The pharmacological relevance of these integrated modules was evaluated with drugs and compared to human and animal data and these results will be presented. There currently is also a focus at the NIH, FDA and EMA to understand how one could validate these systems such that qualification could be granted for their use to augment and possibly replace animal studies. This talk will also give results of six workshops held at NIH as a collaboration between the American Institute for Medical and Biological Engineering (AIMBE) and NIH to explore what is needed for validation and qualification of these new systems.
Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018Organ-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-06-06 09:30:002018-06-06 10:30:00Europe/LondonConcurrent Toxicity and Efficacy Evaluations in Multi-Organ Functional Human-on-a-Chip SystemsOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
